ライフサイエンスコーパス: emollient

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 pared with another intervention or a vehicle/emollient.

2 ents in the control arm were asked to use no emollients.

3 example, fragrances and other ingredients in emollients.

4 or tacrolimus ointment than for steroids and emollients.

5 without the requirement to constantly apply emollients.

6 ty of various topical agents, and the use of emollients.

7 All children and parents received emollient and patient education about AD and basic skin

8 Topically applied formulations (e.g., emollients and moisturizers) may influence the optical p

9 by wearing impermeable gloves) and applying emollients and potent topical glucocorticoids.

10 ally higher in children with frequent use of emollients compared to uncommon users, reaching statisti

11 show that applying a thin layer of glycerine emollient containing nanoparticles of either calcium car

12 ionate, clobetasol propionate, and a vehicle/emollient control.

13 Patients cited topical emollients, corticosteroids, and salicylic acid along wi

14 stamines, topical corticosteroids, and thick emollient creams, rendering their eruption tolerable for

15 measures such as the application of topical emollients have shown mixed results in the prevention of

16 Topical emollients improved neonatal skin condition, but were as

17 sise the evidence for topical application of emollients in the prevention of invasive infection and m

18 Topical emollients might improve skin integrity and barrier func

19 ffect of prophylactic application of topical emollient (ointments, creams, or oils) on the incidence

20 ctive effect was found with the use of daily emollient on the cumulative incidence of atopic dermatit

21 conceivable to design resveratrol-containing emollient or patch, as well as sunscreen and skin-care p

22 ial data do not provide strong evidence that emollients prevent invasive infection or death in preter

23 There were no emollient-related adverse events and no differences in a

24 cidence of infection in infants treated with emollient (relative risk 1.20, 95% CI 1.01-1.42), but no

25 s explained by increased use of the specific emollients that are used to treat pruritic and inflamed

26 ntion arm were instructed to apply full-body emollient therapy at least once per day starting within

27 The results of this trial demonstrate that emollient therapy from birth represents a feasible, safe

28 If confirmed in larger trials, emollient therapy from birth would be a simple and low-c

29 to ascertain whether topical application of emollients to enhance skin barrier function would preven

30 Emollient use and atopic dermatitis were associated with

31 To evaluate the association between emollient use, atopic dermatitis and FLG mutations, resp

32 a vapor-permeable membrane (Gore-Tex) or an emollient (Vaseline), applied after acute barrier disrup

33 formation about atopic dermatitis and use of emollients was obtained from questionnaires completed by

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。